NCT01578421View on ClinicalTrials.gov

Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
DEVICE

4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)

4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements

Trial Locations (1)

CH-5001

Nephrology Division, Kantonsspital Aarau, Aarau

All Listed Sponsors
collaborator

Fresenius Medical Care Deutschland GmbH

INDUSTRY

lead

Kantonsspital Aarau

OTHER

NCT01578421 - Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser | Biotech Hunter | Biotech Hunter